Figures & data
Table 1. Main characteristics of the study sample participants at baseline (ANRS IPERGAY trial, n = 400).
Figure 1. Condom and/or PrEP use reported during the last sexual intercourse (ANRS IPERGAY trial, n = 320 participants with at least one analyzable questionnaire between M2 and M24, corresponding to 1212 sexual intercourse analyzed). Low exposure: anal sex with condoms or oral sex; high exposure: condomless anal sex. *Total: corresponds to the number of sexual intercourses analyzed among the 320 participants between M2 and M24. **Trends were tested for each category: low exposure with PrEP (p = .49); low exposure without PrEP (p = .38); high exposure with PrEP (p = .18); high exposure without PrEP (p = .86).
![Figure 1. Condom and/or PrEP use reported during the last sexual intercourse (ANRS IPERGAY trial, n = 320 participants with at least one analyzable questionnaire between M2 and M24, corresponding to 1212 sexual intercourse analyzed). Low exposure: anal sex with condoms or oral sex; high exposure: condomless anal sex. *Total: corresponds to the number of sexual intercourses analyzed among the 320 participants between M2 and M24. **Trends were tested for each category: low exposure with PrEP (p = .49); low exposure without PrEP (p = .38); high exposure with PrEP (p = .18); high exposure without PrEP (p = .86).](/cms/asset/faef9a85-3447-4c9b-b34f-d85e25e68d37/caic_a_1146653_f0001_b.gif)
Figure 2. Use of PrEP, reported during the last anal sexual intercourse (ANRS IPERGAY trial, n = 259 participants with at least one analyzable questionnaire between M2 and M24; all of them reported at least on recent episode of anal sexual intercourse protected by PrEP use, corresponding to 731 anal sexual intercourses analyzed). PrEP correct use: according to protocol or taking at least 1 pill within 24 h before and 1 pill within 24 h after sex; PrEP suboptimal use: taking at least 1 pill 48 h before or 48 h after sex. *Total: corresponds to the number of anal sexual intercourses protected by using PrEP analyzed among the 259 participants between M2 and M24. **Trends were tested for each category: suboptimal use (p = .50); correct use (p = .50).
![Figure 2. Use of PrEP, reported during the last anal sexual intercourse (ANRS IPERGAY trial, n = 259 participants with at least one analyzable questionnaire between M2 and M24; all of them reported at least on recent episode of anal sexual intercourse protected by PrEP use, corresponding to 731 anal sexual intercourses analyzed). PrEP correct use: according to protocol or taking at least 1 pill within 24 h before and 1 pill within 24 h after sex; PrEP suboptimal use: taking at least 1 pill 48 h before or 48 h after sex. *Total: corresponds to the number of anal sexual intercourses protected by using PrEP analyzed among the 259 participants between M2 and M24. **Trends were tested for each category: suboptimal use (p = .50); correct use (p = .50).](/cms/asset/f083b01c-0e58-44b1-9af6-b64cd7b7d702/caic_a_1146653_f0002_b.gif)